2021-2030 Analysis and Review Neurological Diseases Treatment Market

Neurological Diseases Treatment Market

Neurological Diseases Treatment Market By Type of Drug (Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedative, Analgesics, Antihypertensive, Anticoagulants) By Therapeutic (Epilepsy, Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Cerebrovascular disease) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021 – 2030

16-09-2021 REP-HC-139285 115 pages Format

Request a sample Ask An Analyst Request Methodology

The neurological diseases treatment market is projected to grow at a CAGR of 5.1% during the forecast period from 2021 to 2030. This market is observed as the most diversified and competitive market comprising large number of players globally. The key driving factors assisting the growth of these two segments are rising prevalence of neurological diseases, incessant development in diagnostic technology, and rising awareness associated with early disease diagnosis through awareness campaigns carried out by governmental or non-governmental organizations. However, market entry of efficient drugs in the near future due to presence of strong drug pipeline is expected to impact the market share of traditional drug treatments and further boost the overall growth of this market. Rising research and development activities in the field of neurology has been the key driver for neurological diseases treatment market and is expected to fuel its growth throughout the forecast period (2021 – 2030).

Rising prevalence of neurological disorders related to spine, brain and peripheral nervous system

With changes in lifestyle the frequency of neurological/EEG disorders is increasing significantly. One ofthe most common diseases is epilepsy. The prevalence of epilepsy focuses on the number of people with epilepsy at any given point in time. This comprises people with new onset epilepsy plus those who have had epilepsy for a longtime. Each year, about 150,000 Americans are diagnosed with the central nervous system disorder that causes seizures. Furthermore, it is estimated that over a lifetime, one in 26 people will be diagnosed with it. As per the Centers for Disease Control and Prevention, around 2.3 million American adults suffer from epilepsy. More than 467,000 children have been diagnosed with the central nervous system disorder. According to the facts presented by American Society of Clinical Oncology (ASCO) in 2018, approximately 23,820 U.S. citizens have been diagnosed with brain and spinal cord tumors. There has been a significant rise in peripheral nervous disorder throughout the globe such as neuropathy, sciatica, carpal tunnel syndrome, polyneuropathy, post herpetic neuralgia etc. The primary causes associated with its disease etiology are diabetes, alcoholism, malnutrition, nerve compression, genetic predisposition etc. Significant rise in cranial trauma further accentuates neurological disorders in later stage of human life.

Alzhiemer’s Treatment Drugs Is to Be the Most Potential Segment

The anticholinergic and antiepileptic segment alone contribute to over 44% of the revenue share in 2020. This is largely due to increased focus on R&D in these drugs segment and its application in controlling muscle movement. Increasing prevalence of neurological disorders remains as the key driver to market growth. Based on therapeutic segment, Alzheimer’s disease dominated the market segment in 2020. Intense R&D initiatives are the key reason for the largest share of Alzheimer’s segment, apart from other drivers such as increasing prevalence rate across the globe. Alzheimer’s is also expected to retain its top positon throughout the forecast period. Parkinson’s disease remains as the second largest market for neurological treatment drugs market.

North America is The Largest market while APAC Remains as The Fastest Growing Market

North America accounted for the largest share in global neurological diseases treatment market due to key driving factors such as rising prevalence of neurological diseases, rising awareness associated with early neurological disease diagnosis and treatment, supportive reimbursement policies, & incessant developments in the field of research and development. An estimated 5.4 million Americans have Alzheimer’s disease and today someone in America develops Alzheimer’s disease every 68 seconds. By 2050, there is expected to be one new case of Alzheimer’s disease every 33 seconds, or nearly a million new cases per year, and Alzheimer’s disease prevalence is projected to be 11 million to 16 million. During the forecast period 2021 – 2030, Asia Pacific grew at the fastest rate of 6.3% CAGR from 2021 to 2029 due to emerging market potential that is promising a higher uptake of neurological diseases treatment drugs during the forecast period. The key driving factors include increasing prevalence of neurological disorders, developing healthcare infrastructure, rising awareness associated with neurological diseases which is fueling the rate of diagnosis, and mounting accessibility of modern treatments in developing countries such as China, India, and Indonesia.

Partnerships and Collaborations Are Key Winning Strategies

The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis, GSK, Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc among others.It is evident that drug related activities are the most preferred strategy among the top players. Drug related activities include drug approval across various geographies, presenting clinical trial outcomes, receiving permission to launch neurology drugs in various phases of clinical trials. Strategies such as mergers and acquisitions and partnerships & collaborations are comparatively insignificant in this market.

Historical &Forecast Period

This research report presents the analysis of each segment from 2020 to 2030 considering 2021 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2030.

Report Methodology

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of product categories and region.

By Type of Drug (2020-2030; US$ Mn)

Anticholinergic

Antiepileptic

Antipsychotic

Hypnotic & Sedative

Analgesics

Antihypertensive

Anticoagulants

Others

By Therapeutic Segment (2020-2030; US$ Mn)

Epilepsy

Alzheimer’s disease

Parkinson’s disease

Multiple Sclerosis

Cerebrovascular disease

Others

By Region (2020-2030; US$ Mn)

North America

Europe

Asia Pacific

Latin America

Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Mn)

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key market segments in current scenario and in the future by product categories?
What are the key market segments in current scenario and in the future by regions?
What is the key impact of Covid-19 over market revenues and market determinants in the global neurological treatment market?
What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
How to overcome the current market challenges and leverage the opportunities in each of the market segment?
Who are the key players in the operational predictive maintenance market and what are their key product categories and strategies?
What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc. that companies are deploying to enhance market revenues and growth?

Neurological Diseases Treatment Market - Table of Contents

Chapter 1 Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Scope
1.3.1. Market Segmentation
1.3.2. Years Considered for the Study
1.4. Currency
1.5. Limitation
1.6. Market Stakeholders

Chapter 2 Executive Summary
2.1 Global Neurological Diseases Treatment Market, by Drug Type, 2020 (US$ Bn)
2.2 Global Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 (US$ Bn)

Chapter 3 Impact of Covid 19
3.1 Direct Impact of covid-19 on Neurological Diseases Treatment Market and Healthcare Industry:

Chapter 4 Neurological Diseases Treatment: Market Dynamics and Outlook
4.1 Introduction
4.2 Market Drivers
4.3 Market Restraints
4.4 Opportunities
4.5 Attractive Investment Proposition, by Geography, 2020
4.6 Competitive Landscape: Market Positioning of Neurological Diseases Treatment

Chapter 5 Global Neurological Diseases Treatment Market, by Drug Type
5.1 Global Neurological Diseases Treatment Market, by Drug Type, 2020–2030 (US$ Bn)
5.2 Anticholinergic Drugs
5.3 Antiepileptic Drugs (AEDs) and Other Epileptic Treatment Drugs Used in Combination
5.4 Antipsychotic Drugs
5.5 Hypnotic and Sedatives
5.6 Analgesics
5.7 Antihypertensive Drugs
5.8 Anticoagulants
5.9 Other Drugs for Neurological Disease Treatment

Chapter 6 Global Neurological Diseases Treatment Market, Pipeline Analysis
6.1 Top 10 Neurological Pipeline Drugs 2019
6.2 Phase 3 & Late phase 2 key Neurological Pipeline Drugs 2019
6.3 List of Key Neurological Diseases Treatment Drugs Phase III and Late Phase II Pipeline Drugs, 2019

Chapter 7 Global Neurological Diseases Treatment Market, by Disease/Therapeutic Segment
7.1 Overview
7.2 Global Neurological Diseases Treatment Market, by Therapeutic Segment, 2020–2030 (US$ Bn)
7.3 Alzheimer’s Disease
7.4 Epilepsy
7.5 Parkinson’s Disease
7.6 Multiple Sclerosis
7.7 Cerebrovascular disease
7.8 Other Neurological Therapeutic Segment

Chapter 8 North America Neurological Diseases Treatment Market
8.1 Overview
8.2 North America Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
8.3 North America Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
8.4 North America Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
8.5 The U.S. Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
The U.S. Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
8.6 The U.S. Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
8.7 Canada Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)

Chapter 9 European Union and UK Neurological Diseases Treatment Market
9.1 Overview
9.2 EU and UK Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
9.3 EU and UK Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
9.4 EU and UK Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
9.5 UK Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
9.6 UK Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
9.7 Germany Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
9.8 Germany Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
9.9 France Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
9.10 France Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
9.11 Spain Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
9.12 Spain Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
9.13 Rest of Europe Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
9.14 Rest of Europe Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)

Chapter 10 Asia Neurological Diseases Treatment Market
10.1 Overview
10.2 Asia Pacific Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
10.3 Asia Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
10.4 Asia Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
10.5 Japan Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
10.6 Japan Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
10.7 China Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
10.8 China Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
10.9 India Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
10.10 India Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
10.11 Rest of Asia Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
10.12 Rest of Asia Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)

Chapter 11 Latin America Neurological Diseases Treatment Market
11.1 Overview
11.2 Latin America Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
11.3 Latin America Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
11.4 Latin America Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
11.5 Mexico Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
11.6 Mexico Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
11.7 RoLATAM Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
11.8 RoLATAM Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)

Chapter 12 Middle East and Africa Neurological Diseases Treatment Market
12.1 Overview
12.2 Middle East and Africa Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
12.3 Middle East and Africa Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
12.4 Middle East and Africa Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)

Chapter 13 Company Profiles
13.1 Novartis AG
13.2 GlaxoSmithKline plc
13.3 Merck & Co.
13.4 Bayer AG
13.5 AstraZeneca plc
13.6 Boehringer Ingelheim GmbH
13.7 Teva Pharmaceutical Industries Ltd.
13.8 F. Hoffmann-La Roche AG
13.9 Zogenix, Inc.
13.10 Eisai Co., Ltd.
13.11 AZTherapies, Inc.
13.12 Biogen, Inc.
13.13 Intra-Cellular Therapies, Inc.
13.14 Avid Radiopharmaceuticals
13.15 Avanir Pharmaceuticals
13.16 Johnson & Johnson (Janssen Pharmaceuticals)
13.17 Sunovion Pharmaceuticals Inc.
13.18 AbbVie, Inc.
13.19 NeuroDerm Ltd.
13.20 MedDay Pharmaceuticals SA
13.21 Neurelis, Inc.
13.22 SK Life Science
13.23 Jazz Pharmaceuticals (GW Pharmaceuticals)

Neurological Diseases Treatment Market - List of Tables

TABLE 1 Market Snapshot: Global Neurological Diseases Treatment Market
TABLE 2 Real GDP Growth Rates in Top 10 Countries
TABLE 3 Elevated Debt Level
TABLE 4 World real Per Capita Output in Selected Geographies
TABLE 5 Global Wealth in Per Capita Output in Selected Geographies
TABLE 6 Global Median Income by Country 2021
TABLE 7 GDP by Selected Countries 2019
TABLE 8 Global Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
TABLE 9 Global Neurological Diseases Treatment Market, by Drug Type, 2020–2030, (US$ Bn)
TABLE 10 List of List of Key Neurological Diseases Treatment Drugs Phase III and Late Phase II Pipeline Drugs, 2019
TABLE 11 Global Neurological Diseases Treatment Market, by Dosage, 2020–2030, (US$ Bn)
TABLE 12 North America Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
TABLE 13 North America Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 14 North America Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 15 The U.S. Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 16 The U.S. Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 17 The U.S. Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 18 Canada Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 19 Europe and UK Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
TABLE 20 EU and UK Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 21 EU and UK Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 22 UK Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 23 UK Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 24 Germany Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 25 Germany Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 26 France Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 27 France Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 28 Spain Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 29 Spain Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 30 Rest of Europe Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 31 Rest of Europe Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 32 Asia Pacific Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
TABLE 33 Asia Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 34 Asia Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 35 Japan Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 36 Japan Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 37 China Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 38 China Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 39 India Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 40 India Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 41 Rest of Asia Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 42 Rest of Asia Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 43 Latin America Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
TABLE 44 Latin America Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 45 Latin America Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 46 Mexico Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 47 Mexico Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 48 RoLATAM Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 49 RoLATAM Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)
TABLE 50 Middle East and Africa Neurological Diseases Treatment Market, by Geography, 2020 – 2030 (US$ Bn)
TABLE 51 Middle East and Africa Neurological Diseases Treatment Market, by Drug Type, 2020 – 2030 (US$ Bn)
TABLE 52 Middle East and Africa Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 – 2030 (US$ Bn)

Neurological Diseases Treatment Market - List of Figures

FIG. 1 Global Neurological Diseases Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top-down and Bottom-up Approach
FIG. 3 Global Neurological Diseases Treatment Market, by Drug Type, 2020 (US$ Bn)
FIG. 4 Global Neurological Diseases Treatment Market, by Therapeutic Segment, 2020 (US$ Bn)
FIG. 5 Percentage of Population over 70 by Countries
FIG. 6 Global Geriatric Population Aged 65 and Above, 2014 to 2022 (million)
FIG. 7 Global Percentage Distribution of Geriatric Population Aged 65 and above, 2016 Versus 2050 (million)
FIG. 8 Global Prevalence of Mental Health Disorders, 2012 to 2020 ($ million)
FIG. 9 Global Healthcare Expenditure, 2020 to 2030 ($ million)
FIG. 10 U.S. Healthcare Expenditure, 2020 versus 2030 (% GDP)
FIG. 11 Attractive Investment Proposition, by Geography, 2020
FIG. 12 Global Neurological Diseases Treatment Market, by Geography, 2020 (US$ Bn)
FIG. 13 Key Market Strategies Among Top Market Players - Neurological Diseases Treatment Market – 2020-2021
FIG. 14 Key Market Strategies Among Top Market Players - Neurological Diseases Treatment Market – 2020-2021
FIG. 15 Market Positioning of Key Neurological Diseases Treatment Market Players, 2020
FIG. 16 Global Neurological Diseases Treatment Share by Drug Type, 2020 vs 2029
FIG. 17 Global Neurological Diseases Treatment Market, Anticholinergic Drugs, 2020–2030, (US$ Bn)
FIG. 18 Global Neurological Diseases Treatment Market, Antiepileptic Drugs (AED), 2020–2030 (US$ Bn)
FIG. 19 Global Neurological Diseases Treatment Market, Antipsychotic Drugs, 2020–2030 (US$ Bn)
FIG. 20 Global Neurological Diseases Treatment Market, Hypnotic and Sedatives, 2020–2030 (US$ Bn)
FIG. 21 Global Neurological Diseases Treatment Market, Analgesics, 2020–2030 (US$ Bn)
FIG. 22 Global Neurological Diseases Treatment Market, Antihypertensive Drugs, 2020–2030 (US$ Bn)
FIG. 23 Global Neurological Diseases Treatment Market, Anticoagulants, 2020–2030 (US$ Bn)
FIG. 24 Global Neurological Diseases Treatment Market, Other Drugs, 2020–2030 (US$ Bn)
FIG. 25 Top 10 Neurology Pipeline Drugs, 2025 (Forecast), (US$ Bn)
FIG. 26 Phase 3 and Late Phase 2 - Key Neurological Treatment Drugs Pipeline by Therapeutic Segment, 2019
FIG. 27 Phase 3 and Late Phase 2 - Key Neurological Treatment Drugs Pipeline by Companies, 2019
FIG. 28 Global Neurological Diseases Treatment Share by Therapeutic Segment, 2020 Vs 2029, (%)
FIG. 29 Global Neurological Diseases Treatment Drugs Market, Alzheimer’s Disease, 2020–2030 (US$ Bn)
FIG. 30 Global Neurological Diseases Treatment Drugs Market, Epilepsy, 2020–2030 (US$ Bn)
FIG. 31 Global Neurological Diseases Treatment Drugs Market, Parkinson’s Disease, 2020–2030 (US$ Bn)
FIG. 32 Global Neurological Diseases Treatment Drugs Market, Multiple Sclerosis, 2020–2030 (US$ Bn)
FIG. 33 Global Neurological Diseases Treatment Drugs Market, Cerebrovascular Disease, 2020–2030 (US$ Bn)
FIG. 34 Global Neurological Diseases Treatment Drugs Market, Other Neurological Disease, 2020–2030 (US$ Bn)